Form 4: Evolv Technologies Director Sells Shares

Evolv Technologies Director Michael Ellenbogen exercised options and sold 80,745 shares of Class A Common Stock for approximately $6.91 per share under a pre-arranged trading plan.

Summary

• Michael Ellenbogen, a Director at Evolv Technologies Holdings, Inc. (EVLV), engaged in a pre-planned transaction on December 15, 2025.
• Ellenbogen exercised stock options to acquire 80,745 shares of Class A Common Stock at an exercise price of $0.24 per share.
• Concurrently, he sold 80,745 shares of Class A Common Stock at a weighted average price of $6.91 per share.
• These sales were executed pursuant to a Rule 10b5-1 trading plan established on June 12, 2025.
• The shares were sold in multiple transactions with prices ranging from $6.75 to $7.20.
• Following these transactions, Ellenbogen directly beneficially owns 2,083,961 shares of Class A Common Stock and indirectly owns 151,135 shares through the Family Horizon Trust.
• He also directly holds 1,381,484 stock options.

Sentiment

Score: 5

Explanation: The transaction is a routine insider sale executed under a pre-arranged 10b5-1 plan, which typically reduces the negative signal of an insider sale. It represents a director monetizing vested options, which is common.

Positives

• The transaction was executed under a Rule 10b5-1 trading plan, indicating a pre-scheduled sale not based on immediate insider information.
• The sale price of $6.91 per share is significantly higher than the exercise price of $0.24, indicating a profitable transaction for the director.

Negatives

• A director selling shares could be perceived negatively by the market, potentially signaling a lack of confidence, although the 10b5-1 plan mitigates this to some extent.
• The reduction in direct beneficial ownership by 80,745 shares.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May view the director's sale as a slight negative, but the 10b5-1 plan mitigates concerns about opportunistic selling. The transaction itself does not directly impact company operations or financial health.

Key Dates

Recommendation

This is a routine insider transaction under a 10b5-1 plan, indicating a pre-scheduled sale rather than a reaction to new material information. While an insider sale can sometimes be a negative signal, the pre-planned nature and the director's continued significant holdings (over 2 million shares directly and indirectly, plus 1.3 million options) suggest it's more about personal financial planning than a lack of confidence in the company's future. Therefore, it does not provide a strong signal for a change in investment recommendation.

Keywords

Evolv Technologies, EVLV, Michael Ellenbogen, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Rule 10b5-1 Plan, Director Transaction, Beneficial Ownership